Annals of Surgical Oncology

, Volume 20, Issue 8, pp 2772–2779 | Cite as

S-100B: A Stronger Prognostic Biomarker than LDH in Stage IIIB–C Melanoma

  • K. P. Wevers
  • S. Kruijff
  • M. J. Speijers
  • E. Bastiaannet
  • A. C. Muller Kobold
  • H. J. Hoekstra



In melanoma patients with nodal macrometastases, the distinction between good and poor prognosis is based on the presence of primary melanoma ulceration or metastatic involvement of 4 or more lymph nodes in the 7th edition of the American Joint Committee on Cancer (AJCC) classification. We hypothesized that biomarkers would increase the accurateness of staging in these patients. The aim was to assess and compare the prognostic impact of biomarkers S-100B and LDH and to determine the best timing of their measurement in stage IIIB–C melanoma.


A total of 119 patients underwent therapeutic lymph node dissection (TLND) for nodal macrometastases with serum S-100B and LDH level measurements preoperatively. In 75 of them, S-100B and LDH were also measured on postoperative days 1 and 2. S-100B and LDH levels on days 0, 1, and 2 were compared for their association with disease-free survival (DFS) and disease-specific survival (DSS).


At a median follow-up of 17 (range 1–89) months, S-100B levels at all time points were associated with DFS. In multivariable analysis, preoperative S-100B and S-100B measured on day 2 showed the strongest association with DFS (hazard ratio [HR] 2.55, P = 0.007 and HR 3.80, P = 0.01). For DSS, the preoperative S-100B level was the strongest independent predictor (HR 2.81, P = 0.01). LDH measurements showed a significant association with DSS in univariate analysis only when measured preoperatively (HR 2.46, P = 0.01). In multivariable analysis, LDH measurement was not associated with melanoma prognosis.


The S-100B level measured preoperatively is, in contrast to LDH, one of the most important independent predictors of melanoma prognosis in patients undergoing TLND for nodal macrometastases.



The authors declare no conflict of interest.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Dutch Comprehensive Cancer Centers.
  3. 3.
    Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCrossRefGoogle Scholar
  4. 4.
    Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.PubMedCrossRefGoogle Scholar
  5. 5.
    Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Kruijff S, Hoekstra HJ. The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012;38:281–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898–902.PubMedCrossRefGoogle Scholar
  8. 8.
    Smit LH, Korse CM, Hart AA, et al. Normal values of serum S-100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer. 2005;41:386–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Kruijff S, Bastiaannet E, Kobold AC, et al. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009;16:3455–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Bouwhuis MG, Suciu S, Kruit W, et al. Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer. 2011;47:361–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Tarhini AA, Stuckert J, Lee S, et al. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol. 2009;27:38–44.PubMedCrossRefGoogle Scholar
  12. 12.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCrossRefGoogle Scholar
  13. 13.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedCrossRefGoogle Scholar
  14. 14.
  15. 15.
    Poos HP, Kruijff S, Bastiaannet E, et al. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2009;35:877–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18–26.PubMedCrossRefGoogle Scholar
  17. 17.
    Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.PubMedCrossRefGoogle Scholar
  18. 18.
    Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999;56:338–44.PubMedCrossRefGoogle Scholar
  19. 19.
    Ghanem G, Loir B, Morandini R, et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int J Cancer. 2001;94:586–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Martenson ED, Hansson LO, Nilsson B, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol. 2001;19:824–31.PubMedGoogle Scholar
  21. 21.
    Banfalvi T, Boldizsar M, Gergye M, et al. Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III–IV malignant melanoma. Pathol Oncol Res. 2002;8:183–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Egberts F, Hitschler WN, Weichenthal M, et al. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse. Melanoma Res. 2009;19:31–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Hamberg AP, Korse CM, Bonfrer JM, et al. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin J, Yang Q, Wilder PT, et al. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 2010;285:27487–98.PubMedCrossRefGoogle Scholar
  26. 26.
    Weide B, Elsasser M, Buttner P, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. Br J Cancer. 2012;107:422–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891–6.PubMedGoogle Scholar
  28. 28.
    Egberts F, Pollex A, Egberts JH, et al. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie. 2008;31:380–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Egberts F, Kotthoff EM, Gerdes S, et al. Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer. 2012;48:695–702.PubMedCrossRefGoogle Scholar
  30. 30.
    Garnier JP, Letellier S, Cassinat B, et al. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer. 2007;43:816–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Diaz-Lagares A, Alegre E, Arroyo A, et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol. 2011;32:1155–61.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • K. P. Wevers
    • 1
  • S. Kruijff
    • 1
  • M. J. Speijers
    • 1
  • E. Bastiaannet
    • 1
  • A. C. Muller Kobold
    • 2
  • H. J. Hoekstra
    • 1
  1. 1.Division of Surgical OncologyUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands
  2. 2.Division of Laboratory MedicineUniversity Medical Center Groningen, University of GroningenGroningenThe Netherlands

Personalised recommendations